Your annual physical reports total cholesterol, HDL, and LDL. None of those numbers actually count the atherogenic particles entering your arteries - ApoB does. Cardiologists shifted to ApoB targeting for primary prevention years ago; primary care is still catching up. Here's why ApoB is the better number, what to target, and how to read discordance with standard lipids.
Why LDL alone undercounts risk
LDL-cholesterol (LDL-C) measures the cholesterol mass inside LDL particles. ApoB measures the actual count of atherogenic particles - LDL, VLDL, IDL, and Lp(a) - each carrying one ApoB molecule. Particle count, not cholesterol mass, drives plaque formation.
Discordance: about 1 in 4 adults has LDL-C and ApoB telling different stories. LDL-C of 110 mg/dL with ApoB of 95 mg/dL is moderate risk. LDL-C of 110 with ApoB of 130 is high risk - small dense LDL pattern, more particles per unit cholesterol, more arterial wall penetration.
MESA, UK Biobank, Mendelian randomization studies all converge: ApoB is the better predictor of major adverse cardiovascular events than LDL-C. Every 20 mg/dL drop in ApoB corresponds to roughly 30% lower event risk in primary prevention.
The targets that match modern evidence
Primary prevention, average risk: ApoB under 90 mg/dL. Primary prevention with elevated risk (family history, diabetes, hypertension): ApoB under 80 mg/dL. Secondary prevention (prior event) or aggressive prevention (high Lp(a), strong family history): ApoB under 60-70 mg/dL.
These are stricter than most US guidelines because the guidelines lag the evidence. Lifetime exposure is the engine of atherosclerosis - each decade of high ApoB compounds. Lower, earlier, longer is the cardiology consensus.
Children and young adults can have a lipoprotein profile already plotting their 50-year-old's risk. Pediatric-onset familial hypercholesterolemia is the loudest example, but 25-year-olds with ApoB above 110 carry significant lifetime burden too.
How to read discordance
LDL-C high, ApoB high, both above target: classical pattern. Statin or non-statin therapy plus lifestyle. The numbers agree; the strategy is straightforward.
LDL-C normal, ApoB elevated: small dense LDL pattern - often paired with metabolic syndrome (high triglycerides, low HDL, central adiposity, fatty liver, high HOMA-IR). Treat the metabolic side first; the particle count usually follows.
LDL-C high, ApoB normal: less common. Suggests larger, fluffier LDL particles - lower per-particle risk than the math implied. Doesn't mean no risk; means risk is inside expected range, not magnified.
What moves ApoB
Lifestyle moves ApoB ~10-20%: saturated fat reduction (especially industrial sources), soluble fiber 10+ g/day (oats, beans, psyllium), aerobic + resistance training, fixing visceral adiposity. Diet alone usually caps at ~15% reduction.
Statins reduce ApoB by ~30-50% at moderate-intensity dose; high-intensity statins by 50%+. Ezetimibe adds another 15-20% on top of a statin. PCSK9 inhibitors (injectable) drop ApoB by 50-60% on top of statin therapy. Bempedoic acid adds 15-20% for statin-intolerant patients.
Lp(a): genetic, not modifiable by lifestyle. We measure it once in a lifetime. Above 50 mg/dL (or 125 nmol/L) means more aggressive ApoB targeting - the Lp(a) particles count toward the burden.
What to do now
Run the Advanced lab panel - includes ApoB, full lipid, Lp(a), hs-CRP, fasting insulin, HbA1c. This is the cardiovascular floor for any longevity-focused member.
If ApoB is over 90 (or over 80 with risk factors), book the assessment. We sequence: lifestyle, then statin/ezetimibe/PCSK9 as appropriate. "Diet and exercise" alone often won't hit aggressive prevention targets - we say so plainly.